Background The OPUS study demonstrated that addition of cetuximab to 5-fluorouracil,
folinic acid and oxaliplatin (FOLFOX4) significantly improved objective response and …

3505 Background: The addition of cetuximab to FOLFOX4 significantly improved
progression-free survival and response in the first-line treatment of patients (pts) with KRAS …

Purpose The phase III CRYSTAL study demonstrated that addition of cetuximab to
fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival …

3506 Background: The addition of cetuximab to FOLFIRI significantly improved progression-
free survival, overall survival and response in the first-line treatment of patients (pts) with …

Purpose This randomized study assessed whether the best overall response rate (ORR) of
cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior …

4000 Background: Efficacy analyses of the randomized phase II OPUS trial have previously
failed to show significant improvements in progression-free survival time (PFS) or overall …

Purpose The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as
first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of …

Background The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line
Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status …

Background Following the discovery that mutant KRAS is associated with resistance to anti-
epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic …

Background Patients with metastatic colorectal cancer that harbors KRAS mutations in exon
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …